Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Sep 2:13:970601.
doi: 10.3389/fphar.2022.970601. eCollection 2022.

Metabolic reprogramming: A novel therapeutic target in diabetic kidney disease

Mengdi Wang  1 , Yanyu Pang  1 , Yifan Guo  1 , Lei Tian  1 , Yufei Liu  1 , Cun Shen  1 , Mengchao Liu  1 , Yuan Meng  1 , Zhen Cai  1 , Yuefen Wang  1 , Wenjing Zhao  1
Affiliations
Review

Metabolic reprogramming: A novel therapeutic target in diabetic kidney disease

Mengdi Wang et al. Front Pharmacol. .

Abstract

Diabetic kidney disease (DKD) is one of the most common microvascular complications of diabetes mellitus. However, the pathological mechanisms contributing to DKD are multifactorial and poorly understood. Diabetes is characterized by metabolic disorders that can bring about a series of changes in energy metabolism. As the most energy-consuming organs secondary only to the heart, the kidneys must maintain energy homeostasis. Aberrations in energy metabolism can lead to cellular dysfunction or even death. Metabolic reprogramming, a shift from mitochondrial oxidative phosphorylation to glycolysis and its side branches, is thought to play a critical role in the development and progression of DKD. This review focuses on the current knowledge about metabolic reprogramming and the role it plays in DKD development. The underlying etiologies, pathological damages in the involved cells, and potential molecular regulators of metabolic alterations are also discussed. Understanding the role of metabolic reprogramming in DKD may provide novel therapeutic approaches to delay its progression to end-stage renal disease.

Keywords: diabetic kidney disease; energy metabolism; glycolysis; metabolic reprogramming; mitochondrial oxidative phosphorylation.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Process of energy metabolism in cells.
FIGURE 2
FIGURE 2
Pathological damage induced by metabolic reprogramming of different cells during development of DKD.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Abe Y., Sakairi T., Kajiyama H., Shrivastav S., Beeson C., Kopp J. B. (2010). Bioenergetic characterization of mouse podocytes. Am. J. Physiol. Cell Physiol. 299 (2), C464–C476. 10.1152/ajpcell.00563.2009 - DOI - PMC - PubMed
    1. Ahmad A. A., Draves S. O., Rosca M. (2021). Mitochondria in diabetic kidney disease. Cells 10 (11), 2945. 10.3390/cells10112945 - DOI - PMC - PubMed
    1. Ahn B. H., Kim H. S., Song S., Lee I. H., Liu J., Vassilopoulos A., et al. (2008). A role for the mitochondrial deacetylase Sirt3 in regulating energy homeostasis. Proc. Natl. Acad. Sci. U. S. A. 105 (38), 14447–14452. 10.1073/pnas.0803790105 - DOI - PMC - PubMed
    1. Alicic R. Z., Rooney M. T., Tuttle K. R. (2017). Diabetic kidney disease: Challenges, progress, and possibilities. Clin. J. Am. Soc. Nephrol. 12 (12), 2032–2045. 10.2215/cjn.11491116 - DOI - PMC - PubMed
    1. Alquraishi M., Puckett D. L., Alani D. S., Humidat A. S., Frankel V. D., Donohoe D. R., et al. (2019). Pyruvate kinase M2: A simple molecule with complex functions. Free Radic. Biol. Med. 143, 176–192. 10.1016/j.freeradbiomed.2019.08.007 - DOI - PMC - PubMed